Catalyst OrthoScience Gains Funding to Support Shoulder System

Catalyst OrthoScience Archer CSR

Catalyst OrthoScience raised $12.3 million in an oversubscribed Series D financing round.

Thus far in 2021, Catalyst has:

Rebranded its product portfolio with the Archer family name,
Received FDA 510(k) clearance and began a limited launch for the Archer R1 Reverse Shoulder System and
Introduced its Archer 3D Targeting...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us